Jon Amund Kyte, MD, PhD, University of Oslo, Oslo, Norway discusses the utility of immune checkpoint inhibitors (ICIs) in breast cancer. ICIs have seen success in triple-negative breast cancer (TNBC), however in metastatic setting for HR+ breast cancer, so far there has been a lack of response observed in clinical trials. The Phase IIb ICON (NCT03409198) trial investigated immunogenic chemotherapy with ipilimumab and nivolumab versus chemotherapy alone in HR+ breast cancer and observed no difference between the two arms. For HER2+ breast cancer, ICIs appear to show more promising efficacy. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.